^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug Class:Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    World J Surg Oncol
    Title:

    Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma

    Published date:
    10/13/2023
    Excerpt:
    Mutated EGFR lung adenocarcinoma patients with ever TKI treatment had significantly better survival than with other treatments.
    DOI:
    https://doi.org/10.1186/s12957-023-03203-6
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Rom J Intern Med
    Title:

    Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia

    Published date:
    11/01/2022
    Excerpt:
    This study aims to examine Progression Free Survival (PFS) of positive EGFR mutations advanced lung adenocarcinoma receiving Tyrosine Kinase Inhibitor (TKI) and factors that influence it….Median PFS was 12 months (95% CI 10.28 - 13.71) and minimum PFS was 3 months....Median PFS of EGFR positive mutation advanced lung adenocarcinoma patients who received TKI was 12 months and minimum value was 3 months.
    DOI:
    10.2478/rjim-2022-0020
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P38.05 - Clinical, Genetic, Radiological, and Pathological Characteristics of Cribriform Adenocarcinoma of the Lung

    Published date:
    01/12/2021
    Excerpt:
    Twenty-five patients (2.4%) had Cribri-ADC….Among the 10 patients who had tumor recurrences, 8 had EGFR mutations or ALK rearrangement, 6 of whom achieved relatively long survival (median, 64.6 months; range, 37.4–113 months) following treatment with tyrosine kinase inhibitors (TKIs).
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Thorac Dis
    Title:

    Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection

    Excerpt:
    From August 2009 to February 2015, 338 patients with pT1a and pT1b invasive lung adenocarcinoma who underwent EGFR mutation analysis were enrolled into this study….Tyrosine kinase inhibitors (TKIs) could significantly prolong the OS in patients with EGFR mutation after recurrence (P=0.04).
    DOI:
    10.21037/jtd-21-924